-
Recombinant BRD7 (129-236) protein
Recombinant BRD7 (129-236) protein
- 中文名称：
- Recombinant BRD7 (129-236) protein
- 英文名称：
- Recombinant BRD7 (129-236) protein
- 品牌：
- AAA Biotech
- 品牌介绍：
- AAA Biotech专注于为全球生命科学研究提供高品质的蛋白质研究工具，核心产品包括经严格验证的抗体、重组蛋白及ELISA试剂盒。
- 货号：
- AAA59649
- 规格：
- 0.1 mg|1 mg|2x1 mg|3x1 mg|4x1 mg
- 保存建议：
- Recombinant proteins in solution are temperature sensitive and must be stored at -80 degree C to prevent degradation. Avoid repeated freeze/thaw cycles and keep on ice when not in storage.
Shipping Temp: Dry Ice
- 货期：
- 6-8周
- 纯度：
- The recombinant protein is >85% pure by SDS-PAGE.
- 产品形式：
- Recombinant BRD7 (129-236) protein expressed in E Coli and supplied in 25mM Tris pH8.0, 500mM NaCl, 0.04% Triton X-100, 20% glycerol.
- 免责声明：
- *本产品仅供科研实验使用，不得用于临床诊断。*
- 说明书：
Short Description: The peptide corresponding to amino acids 129-236 that contains the bromodomain sequences of BRD7 (accession number NM_013263.4) was expressed in E Coli and contains an N-terminal His-tag and C-terminal DYKDDDDK tag with an observed molecular weight of 18.8 kDa. Bromodomain-containing protein 7 (BRD7) belongs to the BET subclass of proteins, which are characterized by two N-terminal bromodomains and one ET (Extra Terminal) domain. BRDs associate with chromatin through their bromodomains that recognize acetylated histone lysine residues. Bromodomains function as 'readers' of these epigenetic histone marks and regulate chromatin structure and gene expression by linking associated proteins to the acetylated nucleosomal targets. The ET domain functions as a protein binding motif and exerts atypical serine-kinase activity. The BET family consists of at least four members in mouse and human, BRD2 (also referred to as FSRG1, RING3), BRD3 (FSRG2, ORFX), BRD4 (FSRG4, MCAP/HUNK1), and BRDT (FSRG3, BRD6). BRD7 interacts with several proteins, including DVL1, PTPN13, IRF2 and HNRPUL1 and functions in the regulation of transcriptional activation and chromatin remodeling. Specifically, BRD7 has been shown to bind dishevelled-1 (DVL1) and enhance Wnt signaling via inhibition of GSK3b. BRD7 also associates with histones and E1B-AP5. In particular, it binds acetylated histone peptides, most notably H3 peptide acetylated at Lys14. BRD7 also inhibits G1-S progression by transcriptional regulation of molecules in the Ras and Rb pathways. BRD7 also suppresses tumorigenicity through binding and acetylation of p53 that results in efficient recruitment of p53 to target promoters and subsequent oncogene-induced senescence.
Background: Bromodomain-containing protein 7 (BRD7) belongs to the BET subclass of proteins, which are characterized by two N-terminal bromodomains and one ET (Extra Terminal) domain. BRDs associate with chromatin through their bromodomains that recognize acetylated histone lysine residues. Bromodomains function as 'readers' of these epigenetic histone marks and regulate chromatin structure and gene expression by linking associated proteins to the acetylated nucleosomal targets. The ET domain functions as a protein binding motif and exerts atypical serine-kinase activity. The BET family consists of at least four members in mouse and human, BRD2 (also referred to as FSRG1, RING3), BRD3 (FSRG2, ORFX), BRD4 (FSRG4, MCAP/HUNK1), and BRDT (FSRG3, BRD6). BRD7 interacts with several proteins, including DVL1, PTPN13, IRF2 and HNRPUL1 and functions in the regulation of transcriptional activation and chromatin remodeling. Specifically, BRD7 has been shown to bind dishevelled-1 (DVL1) and enhance Wnt signaling via inhibition of GSK3b. BRD7 also associates with histones and E1B-AP5. In particular, it binds acetylated histone peptides, most notably H3 peptide acetylated at Lys14. BRD7 also inhibits G1-S progression by transcriptional regulation of molecules in the Ras and Rb pathways. BRD7 also suppresses tumorigenicity through binding and acetylation of p53 that results in efficient recruitment of p53 to target promoters and subsequent oncogene-induced senescence.
